Endocrine resistance—a major cause of breast cancer deaths—can be underpinned by an epigenetic change called DNA methylation, researchers at the Garvan Institute of Medical Research have discovered.
Zenith Epigenetics Ltd. ("Zenith" or the "Company") today announced that the Company has received clearance from the US Food and Drug Administration ("FDA") to sponsor a registration enabling study ...
Epithelioid sarcoma, a rare aggressive cancer that usually strikes young adults, and rhabdoid tumors, which affect children, have long been difficult to treat. But the outlook for people with these ...
This review is designed by Dr. Yinglan Zhao and written by her PhD students Dr. Lei Tao and Yue Zhou (Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University).
SAN FRANCISCO, August 11, 2026--(BUSINESS WIRE)--Epicrispr Biotechnologies, a clinical-stage biotechnology company pioneering programmable epigenetic medicines, today announced the closing of a $90 ...
Next-generation epigenetic therapy showed stronger anti-leukemia activity than current standard treatments in preclinical models of acute myeloid leukemia (AML) The drug remained effective in ...
Epicrispr Biotechnologies has closed an oversubscribed $90 million Series C financing to advance EPI-321 toward pivotal clinical development for facioscapulohumeral muscular dystrophy, or FSHD. The ...
Researchers have revealed a reason why endocrine resistance develops in breast cancers and how to potentially treat it in patients. Endocrine resistance -- a major cause of breast cancer deaths -- can ...
Epigenome remodeling, including widespread changes to DNA methylation and 3D chromatin structure, is increasingly recognized as an important mechanism of gene deregulation in cancer. For example, at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results